智通财经网·2025-09-09 06:14Core Viewpoint - Zhaoyan New Drug (06127) experienced a decline of over 7%, closing at HKD 20.98 with a trading volume of HKD 147 million due to insider selling announcements [1] Group 1: Insider Selling Announcements - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through block trades or centralized bidding on the Shanghai Stock Exchange, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - The planned reductions include 674,700 shares from Sun Yunxia, 72,100 shares from Gao Dapeng, and 67,400 shares from Gu Jingliang, along with additional reductions from supervisor Li Ye and CFO Yu Aishui [1] Group 2: Previous Insider Selling - On September 1, Zhaoyan New Drug disclosed that former Vice Chairman Zuo Conglin had a reduction plan announced on August 14, 2025, intending to sell up to 3,524,500 shares between August 19, 2025, and August 29, 2025, which would account for 0.4703% of the company's total share capital at that time [2] - By August 29, 2025, Zuo Conglin had successfully reduced his holdings by 2,264,900 shares through centralized bidding [2]